The article discusses the groundbreaking advancements in pancreatic cancer treatment, highlighting the experimental drug daraxonrasib, which has shown promising results in extending patient survival and targets the previously deemed "untreatable" KRAS protein, marking a significant shift in research and treatment approaches after decades of failures in this field. #PancreaticCancer #CancerResearch #TargetedTherapy #US #CA #EU #HI
www.nytimes.com
El cáncer de páncreas tiene un gran avance
